Skip to main content
Explore URMC

menu

A study of Duvelisib, an oral medicine to treat Peripheral T Cell Lymphoma (PTCL)

Research Question:
What is the effect of oral medicine, duvelisib, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL)?

Basic Study Information

Purpose:
This is a multi-center, open-label study of duvelisib (brand name Copiktra), an oral medicine to treat patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).

Location: University of Rochester Medical Center
Study Reference #: ILYM-17121

Lead Researcher (Principal Investigator)

Lead Researcher: Carla Casulo

Study Contact Information

Study Coordinator: Yelena Lerman
Phone: (585) 276-8333
Email: ylerman@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search